序号 |
标题 |
次数 |
作者 |
发布时间 |
67456 |
(LLP2A-DOTA)(4)PEG(10000) |
68 |
h |
2024-12-19 |
67457 |
LLP2A-DOTA-聚乙二醇 LLP2A-DOTA-PEG |
62 |
h |
2024-12-19 |
67458 |
DOTA-AaLS/HER2Afb HER2Afb修饰DOTA缀合的AaLS-ST |
81 |
h |
2024-12-19 |
67459 |
DOTA-P4 Thz-Phe-D-Trp-Lys-Thr-DOTA DOTA的线型超短肽缀合物 |
89 |
h |
2024-12-19 |
67460 |
DOTA-BP DOTA偶联双膦酸盐 |
112 |
h |
2024-12-19 |
67461 |
DOTA缀合的p160肽基放射缀合物 DOTA-p160 |
85 |
h |
2024-12-19 |
67462 |
DOTA-氮氧化合物 DOTA-NOx |
78 |
h |
2024-12-19 |
67463 |
Er-DOTA 铒-DOTA配合物 |
80 |
h |
2024-12-19 |
67464 |
DOTA-SETSKSF DOTA偶联七个氨基酸残基组成的环肽抑制剂 |
120 |
h |
2024-12-19 |
67465 |
羧基Bn-DOTA p-COOH-Bn-DOTA |
68 |
h |
2024-12-19 |
67466 |
DOTA四酰肼钆(ⅲ)配合物 |
74 |
h |
2024-12-19 |
67467 |
3-Gd(III)-氨基乙基酰胺基-DOTA的缀合物 |
102 |
h |
2024-12-19 |
67468 |
TCO功能化的CC49抗体 TCO-CC49 |
155 |
h |
2024-12-19 |
67469 |
CLT1肽靶向Gd(III)螯合物 CLT1-dL-(Gd-DOTA) |
97 |
h |
2024-12-19 |
67470 |
DOTA-pNO(2)-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)DTyrNH |
109 |
h |
2024-12-19 |
67471 |
Gd-DOTA-PLGA-b-PEG 钆-四氮杂环十二烷四乙酸共轭的聚(乳酸-共-乙醇酸)-嵌段-聚(乙二醇)共聚物胶束 |
108 |
h |
2024-12-19 |
67472 |
DOTA聚乙二醇化星形共聚物纳米粒子 |
80 |
h |
2024-12-19 |
67473 |
镓-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸-Ser-Ser-Ser-Leu-Thr-Val-Ser-Pro-Trp-Tyr |
101 |
h |
2024-12-19 |
67474 |
DOTA-C595 p-SCN-Bn-DOTA偶联C595抗体 |
133 |
h |
2024-12-19 |
67475 |
DOTA-Tyr3-奥曲肽 DOTA-Tyr3-TOC |
77 |
h |
2024-12-19 |
67476 |
DOTA-生物素-亲和素 DOTA-biotin-avidin |
55 |
h |
2024-12-19 |
67477 |
DOTA-AuNPs 螯合剂DOTA包覆金纳米颗粒 |
91 |
h |
2024-12-19 |
67478 |
PS-WSCS-DOTA-BBN 水溶性壳聚糖缀合的DOTA-铃蟾肽包覆的金纳米颗粒 |
69 |
h |
2024-12-19 |
67479 |
苄基DOTA Bn-DOTA |
163 |
h |
2024-12-19 |
67480 |
DOTA-LM3 生长抑素受体(SSTR)拮抗剂 |
95 |
h |
2024-12-19 |
67481 |
Ga-DOTA-MGS5 大环配体-靶向肽 |
92 |
h |
2024-12-19 |
67482 |
Re-cyc-DOTA-sst2-ANT复合物 |
87 |
h |
2024-12-19 |
67483 |
DOTA-SP DOTA-P物质(SP) |
88 |
h |
2024-12-19 |
67484 |
DOTA-MG45 DOTA偶联迷你胃泌素(MG45) |
87 |
h |
2024-12-19 |
67485 |
DOTA-甘露糖胺葡聚糖 DOTA-MADs |
75 |
h |
2024-12-19 |
67486 |
ICG-DOTA 大环配体DOTA修饰吲哚菁绿荧光染料 |
100 |
h |
2024-12-18 |
67487 |
DOTA-SSA 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)-生长抑素类似物(SSA) |
76 |
h |
2024-12-18 |
67488 |
DOTA螯合剂修饰[cPP(1-7) |
137 |
h |
2024-12-18 |
67489 |
DOTA-ALB-24 DOTA-4-(对碘苯基)丁酸酯-24 |
87 |
h |
2024-12-18 |
67490 |
DOTA-GGNle-CycMSH hex DOTA偶联新肽 |
108 |
h |
2024-12-18 |
67491 |
Zr-p-NO2Bn-DOTA异构体 锆-硝基苄基偶联DOTA螯合剂 |
99 |
h |
2024-12-18 |
67492 |
DOTA-PSMA-617 1,4,7,10-四氮杂环十五烷偶联PSMA-617 |
79 |
h |
2024-12-18 |
67493 |
DOTA-VAP-1 螯合剂DOTA偶联VAP-1靶向肽 |
136 |
h |
2024-12-18 |
67494 |
DOTA-GIP-C803 DOTA螯合剂缀合GIPC803肽 |
67 |
h |
2024-12-18 |
67495 |
DOTA-mPS 螯合剂DOTA修饰微米级聚苯乙烯 |
99 |
h |
2024-12-18 |
67496 |
DOTA-HBED-bisphosphonate DOTA-HBED-二膦酸盐 |
97 |
h |
2024-12-18 |
67497 |
CAS号:2226472-28-0 ,DBCO-PEG4-Val-Cit-PAB-PNP |
99 |
WYQ |
2024-12-18 |
67498 |
cas:2112738-09-5, Mal-PEG4-Val-Cit-PAB-PNP |
109 |
WYQ |
2024-12-18 |
67499 |
Mal-PEG8-Val-Cit-PAB-PNP,可以溶解于DCM、DMF、DMSO、THF等有机溶剂,以及水中。 |
111 |
WYQ |
2024-12-18 |
67500 |
Mal-PEG2-Val-Ala-PAB-PNP,含有马来酰亚胺(Mal)官能团、两个单元的聚乙二醇(PEG2)间隔物、缬氨酸(Val)和丙氨酸(Ala)的序列 |
68 |
WYQ |
2024-12-18 |